 |
160 Products |  |
813 Diseases | | 160 Products |
|
1588 Trials |  |
77929 News |  |
| «12...886887888889890891892893894895896...903904» |
- AMG 151 / Amgen
New P1 trial: Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects (clinicaltrials.gov) - Dec 20, 2012
P1, N=5, Terminated, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma (clinicaltrials.gov) - Dec 20, 2012
P2, N=14, Completed, Sponsor: University Hospital Tuebingen
Recruiting --> Completed
- Genasense (oblimersen) / Genta
Trial termination, Combination therapy, IO biomarker, Metastases: Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Dec 18, 2012
P1/2, N=69, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Completed --> Terminated
- || Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, HEOR, Real-world evidence, Real-world: Characterize Patients With Moderately Active Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Dec 18, 2012
P=N/A, N=1754, Completed, Sponsor: Pfizer
Completed --> Terminated N=1000 --> 1754
- Enrollment change, Metastases: Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma (clinicaltrials.gov) - Dec 18, 2012
P2, N=170, Completed, Sponsor: National Cancer Institute (NCI)
N=1000 --> 1754 N=220 --> 170
- ||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis (clinicaltrials.gov) - Dec 18, 2012
P4, N=68, Active, not recruiting, Sponsor: Eli Lilly and Company
- Campath (alemtuzumab) / Sanofi
Trial completion: Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 18, 2012
P1/2, N=302, Completed, Sponsor: National Cancer Institute (NCI)
N=220 --> 170 Active, not recruiting --> Completed
- ||||| Epogen (epoetin alfa) / Amgen
Trial initiation date, Metastases: A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy (clinicaltrials.gov) - Dec 17, 2012
P3, N=2100, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Initiation date: Nov 2005 --> Mar 2006
- ||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
New P2 trial: Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim (clinicaltrials.gov) - Dec 17, 2012
P2, N=300, Recruiting, Sponsor: Amgen
- Enbrel (etanercept) / Pfizer, Amgen, Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
Enrollment closed: Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant (clinicaltrials.gov) - Dec 17, 2012
P2, N=48, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Initiation date: Nov 2005 --> Mar 2006 Recruiting --> Active, not recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: The Use of Etanercept (Enbrel (clinicaltrials.gov) - Dec 17, 2012
P2, N=40, Completed, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment open: Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim (clinicaltrials.gov) - Dec 16, 2012
P2, N=300, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- dilanubicel (DVX101) / Deverra Therapeutics
Enrollment open: Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 16, 2012
P=N/A, N=15, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Adverse events: Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 16, 2012
P2, N=80, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Prolia (denosumab) / Amgen, Daiichi Sankyo
New P4 trial: Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption (clinicaltrials.gov) - Dec 13, 2012
P4, N=40, Recruiting, Sponsor: Massachusetts General Hospital
- ||||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
New P2 trial: BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) (clinicaltrials.gov) - Dec 13, 2012
P2, N=200, Recruiting, Sponsor: GlaxoSmithKline
- Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open: Effect of Denosumab on Inflammatory Osteolytic Lesion Activity in Total Hip Arthroplasty (clinicaltrials.gov) - Dec 13, 2012
P2, N=30, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- conatumumab (AMG 655) / Amgen
Trial withdrawal, Metastases: Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2012
P1/2, N=0, Withdrawn, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- | ivabradine / Generic mfg.
Enrollment change: Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation in patients with chronic heart failure and left ventricular systolic dysfunction (EUDRACT) - Dec 11, 2012
P3, N=700, Ongoing, Sponsor: Institut de Recherches Internationales Servier`Laboratorios Servier S. L.`INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
Not yet recruiting --> Withdrawn N=80 --> 700
- | ivabradine / Generic mfg.
Enrollment change: Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease (EUDRACT) - Dec 11, 2012
P3, N=700, Ongoing, Sponsor: Institut de Recherches Internationales Servier`Laboratorios Servier S.L.`INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
N=80 --> 700 N=120 --> 700
- conatumumab (AMG 655) / Amgen
Enrollment change, Metastases: Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 11, 2012
P1/2, N=0, Withdrawn, Sponsor: Radiation Therapy Oncology Group
N=120 --> 700 N=89 --> 0
- |||| trebananib (AMG 386) / Amgen
Trial completion, Combination therapy, Metastases: Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma (clinicaltrials.gov) - Dec 11, 2012
P2, N=171, Completed, Sponsor: Amgen
N=89 --> 0 Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Dec 10, 2012
P3, N=720, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial termination: REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer (clinicaltrials.gov) - Dec 9, 2012
P3, N=574, Terminated, Sponsor: Royal Marsden NHS Foundation Trust
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of efficacy
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant (clinicaltrials.gov) - Dec 9, 2012
P2, N=0, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Terminated; Lack of efficacy Active, not recruiting --> Terminated; low accrual
- Vectibix (panitumumab) / Amgen
Enrollment change: REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer (clinicaltrials.gov) - Dec 9, 2012
P3, N=574, Terminated, Sponsor: Royal Marsden NHS Foundation Trust
Active, not recruiting --> Terminated; low accrual N=730 --> 574
- Erbitux (cetuximab) / Eli Lilly
Enrollment change: ERBIFORT: Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung (clinicaltrials.gov) - Dec 9, 2012
P2, N=24, Completed, Sponsor: National Cancer Institute, France
N=730 --> 574 N=36 --> 24
- ||||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Dec 9, 2012
P2, N=180, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- bisnorcymserine (ANVS-301) / Annovis Bio
New P1 trial: Bisnorcymserine in Healthy Adult Volunteers (clinicaltrials.gov) - Dec 9, 2012
P1, N=200, Recruiting, Sponsor: National Institute on Aging (NIA)
- Erbitux (cetuximab) / Eli Lilly
Trial completion: ERBIFORT: Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung (clinicaltrials.gov) - Dec 9, 2012
P2, N=24, Completed, Sponsor: National Cancer Institute, France
N=36 --> 24 Recruiting --> Completed
- melphalan / Generic mfg., busulfan / Generic mfg., gemcitabine / Generic mfg.
New P2 trial: CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma (clinicaltrials.gov) - Dec 6, 2012
P2, N=24, Recruiting, Sponsor: Dana-Farber Cancer Institute
- | Procysbi (cysteamine bitartrate delayed release) / Amgen
New P3 trial: Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis (clinicaltrials.gov) - Dec 5, 2012
P3, N=10, Recruiting, Sponsor: Raptor Pharmaceuticals Inc.
- | abexinostat (CG-781) / Xynomic
Enrollment closed, Combination therapy, Metastases: PCI-24781 in Combination With Doxorubicin to Treat Sarcoma (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=47, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Recruiting --> Active, not recruiting
- Kepivance (palifermin) / SOBI, Amgen
Trial completion, IO biomarker: Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Dec 4, 2012
P=N/A, N=6, Completed, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial termination: Panitumumab and Irinotecan for Malignant Gliomas (clinicaltrials.gov) - Dec 3, 2012
P2, N=16, Terminated, Sponsor: Annick Desjardins
Active, not recruiting --> Completed Active, not recruiting --> Terminated; study did not reach benchmark efficacy rule at 16 subjects
- Vectibix (panitumumab) / Amgen
Enrollment change: Panitumumab and Irinotecan for Malignant Gliomas (clinicaltrials.gov) - Dec 3, 2012
P2, N=16, Terminated, Sponsor: Annick Desjardins
Active, not recruiting --> Terminated; study did not reach benchmark efficacy rule at 16 subjects N=32 --> 16
- New P4 trial: A randomised controlled trial to compare withdrawal of therapy versus continuing therapy in low disease states in psoriatic arthritis (EUDRACT) - Dec 3, 2012
P4, N=30, Ongoing, Sponsor: University of Leeds
- | Blincyto (blinatumomab) / Astellas, Amgen
New P2 trial: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Dec 3, 2012
P2, N=25, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH
- Neulasta (pegfilgrastim) / Roche
Enrollment change: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Dec 2, 2012
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
N=32 --> 16 N=41 --> 55
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, IO biomarker: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) (clinicaltrials.gov) - Dec 2, 2012
P3, N=450, Recruiting, Sponsor: Pfizer
- ||||| Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Dec 2, 2012
P1/2, N=149, Recruiting, Sponsor: Amgen
- melphalan / Generic mfg., amifostine / Generic mfg.
Trial termination: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Nov 29, 2012
P1, N=8, Terminated, Sponsor: Eastern Cooperative Oncology Group
N=41 --> 55 Active, not recruiting --> Terminated; Slow accrual and changes in clinical practice
- melphalan / Generic mfg., amifostine / Generic mfg.
Enrollment change: Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Nov 29, 2012
P1, N=8, Terminated, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Terminated; Slow accrual and changes in clinical practice N=46 --> 8
- | Krystexxa (pegloticase) / Amgen
New P1 trial: Study to Assess Pegloticase (KRYSTEXXA (clinicaltrials.gov) - Nov 29, 2012
P1, N=12, Completed, Sponsor: Savient Pharmaceuticals
- epirubicin / Generic mfg.
Trial completion, Surgery: Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - Nov 29, 2012
P2, N=15, Completed, Sponsor: Case Comprehensive Cancer Center
N=46 --> 8 Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
New P4 trial: Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis (clinicaltrials.gov) - Nov 28, 2012
P4, N=41, Terminated, Sponsor: Amgen
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
New P1 trial: Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency (clinicaltrials.gov) - Nov 28, 2012
P1, N=13, Completed, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change, Surgery: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Nov 27, 2012
P3, N=15, Terminated, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed N=240 --> 15
- |||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment open: NOLAN: Naproxen or Loratadine and Neulasta (clinicaltrials.gov) - Nov 27, 2012
P2, N=600, Recruiting, Sponsor: Amgen
N=240 --> 15 Not yet recruiting --> Recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Enrollment closed: Reversing Type 1 Diabetes After it is Established (clinicaltrials.gov) - Nov 27, 2012
P1/2, N=25, Active, not recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting